177 related articles for article (PubMed ID: 17998899)
1. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy.
Gratzinger D; Zhao S; Tibshirani RJ; Hsi ED; Hans CP; Pohlman B; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Lossos IS; Natkunam Y
Lab Invest; 2008 Jan; 88(1):38-47. PubMed ID: 17998899
[TBL] [Abstract][Full Text] [Related]
2. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.
Gratzinger D; Zhao S; Marinelli RJ; Kapp AV; Tibshirani RJ; Hammer AS; Hamilton-Dutoit S; Natkunam Y
Am J Pathol; 2007 Apr; 170(4):1362-9. PubMed ID: 17392174
[TBL] [Abstract][Full Text] [Related]
3. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Gratzinger D; Advani R; Zhao S; Talreja N; Tibshirani RJ; Shyam R; Horning S; Sehn LH; Farinha P; Briones J; Lossos IS; Gascoyne RD; Natkunam Y
Br J Haematol; 2010 Jan; 148(2):235-44. PubMed ID: 19821819
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas.
Kim JS; Gang GW; Lee SR; Sung HJ; Park Y; Kim DS; Choi CW; Kim BS
Jpn J Clin Oncol; 2015 Oct; 45(10):914-20. PubMed ID: 26185139
[TBL] [Abstract][Full Text] [Related]
5. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
Wang ES; Teruya-Feldstein J; Wu Y; Zhu Z; Hicklin DJ; Moore MA
Blood; 2004 Nov; 104(9):2893-902. PubMed ID: 15238424
[TBL] [Abstract][Full Text] [Related]
6. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.
Cardesa-Salzmann TM; Colomo L; Gutierrez G; Chan WC; Weisenburger D; Climent F; González-Barca E; Mercadal S; Arenillas L; Serrano S; Tubbs R; Delabie J; Gascoyne RD; Connors JM; Mate JL; Rimsza L; Braziel R; Rosenwald A; Lenz G; Wright G; Jaffe ES; Staudt L; Jares P; López-Guillermo A; Campo E
Haematologica; 2011 Jul; 96(7):996-1001. PubMed ID: 21546504
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
[TBL] [Abstract][Full Text] [Related]
8. [Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system].
Tang QL; Jiang XF; Yang KZ; Li HG; Liu WP; Peng ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):48-51. PubMed ID: 19292043
[TBL] [Abstract][Full Text] [Related]
9. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients.
Ganjoo KN; Moore AM; Orazi A; Sen JA; Johnson CS; An CS
J Cancer Res Clin Oncol; 2008 Mar; 134(3):381-7. PubMed ID: 17694324
[TBL] [Abstract][Full Text] [Related]
10. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas.
Jørgensen JM; Sørensen FB; Bendix K; Nielsen JL; Funder A; Karkkainen MJ; Tainola T; Sørensen AB; Pedersen FS; D'Amore F
Leuk Lymphoma; 2009 Oct; 50(10):1647-60. PubMed ID: 19701853
[TBL] [Abstract][Full Text] [Related]
11. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
12. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Riihijärvi S; Nurmi H; Holte H; Björkholm M; Fluge O; Pedersen LM; Rydström K; Jerkeman M; Eriksson M; Leppä S
Eur J Haematol; 2012 Nov; 89(5):395-402. PubMed ID: 22882209
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Michallet AS; Warzocha K; Biliński P; Boyle P; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2013 Apr; 61(2):165-74. PubMed ID: 23283519
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis in nodal B cell lymphomas: a high throughput study.
Tzankov A; Heiss S; Ebner S; Sterlacci W; Schaefer G; Augustin F; Fiegl M; Dirnhofer S
J Clin Pathol; 2007 May; 60(5):476-82. PubMed ID: 16790692
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Liu Z; Xu-Monette ZY; Cao X; Manyam GC; Wang X; Tzankov A; Xia Y; Li X; Visco C; Sun R; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; O'Malley DP; Medeiros LJ; Young KH
Mod Pathol; 2015 Oct; 28(10):1297-314. PubMed ID: 26248897
[TBL] [Abstract][Full Text] [Related]
16. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas.
Pazgal I; Boycov O; Shpilberg O; Okon E; Bairey O
Leuk Lymphoma; 2007 Nov; 48(11):2213-20. PubMed ID: 17926187
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma.
Shahini L; Gašparov S; Petruševska G; Manxhuka Kerliu S; Veselaj F; Kurshumliu F; Kavaja F
Acta Clin Croat; 2017 Dec; 56(4):588-593. PubMed ID: 29590710
[TBL] [Abstract][Full Text] [Related]
18. Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Yoon KA; Kim MK; Eom HS; Lee H; Park WS; Sohn JY; Kim MJ; Kong SY
Leuk Lymphoma; 2017 Nov; 58(11):2677-2682. PubMed ID: 28326867
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.
Riihijärvi S; Koivula S; Nyman H; Rydström K; Jerkeman M; Leppä S
Mod Pathol; 2010 May; 23(5):686-93. PubMed ID: 20190733
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
Powell JR; Dojcinov S; King L; Wosniak S; Gerry S; Casbard A; Bailey H; Gallop-Evans E; Maughan T
Leuk Lymphoma; 2013 May; 54(5):959-66. PubMed ID: 23020605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
